GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Denali Therapeutics Inc (STU:4DN) » Definitions » Sale Of Business

Denali Therapeutics (STU:4DN) Sale Of Business : €0.0 Mil (TTM As of Sep. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Denali Therapeutics Sale Of Business?

Denali Therapeutics's sale of business for the three months ended in Sep. 2024 was €0.0 Mil. It means Denali Therapeutics gained €0.0 Mil from selling business. Denali Therapeutics's sale of business for the trailing twelve months (TTM) ended in Sep. 2024 was €0.0 Mil.

Compared with last quarter (€0.0 Mil in Jun. 2024 ), Denali Therapeutics gained the same money from selling business in Sep. 2024 (€0.0 Mil).


Denali Therapeutics Sale Of Business Historical Data

The historical data trend for Denali Therapeutics's Sale Of Business can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Denali Therapeutics Sale Of Business Chart

Denali Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Sale Of Business
Get a 7-Day Free Trial Premium Member Only - - - - -

Denali Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Sale Of Business Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Denali Therapeutics Sale Of Business Calculation

The amount earned to sell business.


Sale Of Business for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Denali Therapeutics Sale Of Business Related Terms

Thank you for viewing the detailed overview of Denali Therapeutics's Sale Of Business provided by GuruFocus.com. Please click on the following links to see related term pages.


Denali Therapeutics Business Description

Traded in Other Exchanges
Address
161 Oyster Point Boulevard, South San Francisco, CA, USA, 94080
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.

Denali Therapeutics Headlines

No Headlines